Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC.AGIO · Entity 4499 | Director | June 18, 2026 | June 23, 2026 |
| Carisma Therapeutics Inc.CARM · Entity 74418 | Director | July 01, 2024 | July 01, 2024 |
| Dianthus Therapeutics, Inc. /DE/MGTA · Entity 1813 | Director | June 28, 2022 | June 30, 2022 |
| Editas Medicine, Inc.EDIT · Entity 5502 | Director | June 17, 2026 | June 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AGIOS PHARMACEUTICALS, INC.
Report date June 18, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stockSEC Table I · non-derivative | Direct | 20,419 |
Reported balance
After 2026-06-18 transaction · row 1
1 source rowRow 1 · 2026-06-18 · Exercise / conversion · Acquired 2,816 · Balance 20,419 |
| Restricted stock unitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-18 · Exercise / conversion · Disposed 2,816 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2: The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested. |
| Restricted stock unitsSEC Table II · derivative / convertible security | Direct | 2,927 |
Reported balance
After 2026-06-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-18 · Grant · Acquired 2,927 · Balance 2,927 F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3: The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested. |
| Stock options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.16 · Expires 2036-06-18 | Direct | 14,950 |
Reported balance
After 2026-06-18 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-18 · Grant · Acquired 14,950 · Balance 14,950 F4: These options were granted on June 18, 2026. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
F2: The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested.
F3: The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested.
F4: These options were granted on June 18, 2026. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2027.
Carisma Therapeutics Inc.
Report date July 01, 2024 · Filed July 01, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.67 · Expires 2034-07-01 | Direct | 38,700 |
Reported balance
After 2024-07-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-07-01 · Grant · Acquired 38,700 · Balance 38,700 F1: The shares underlying this option vest over three years in equal monthly installments following July 1, 2024, subject to continued service to Carisma Therapeutics Inc. through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option vest over three years in equal monthly installments following July 1, 2024, subject to continued service to Carisma Therapeutics Inc. through the applicable vesting date.
Dianthus Therapeutics, Inc. /DE/
Report date June 28, 2022 · Filed June 30, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.21 · Expires 2032-06-27 | Direct | 20,000 |
Reported balance
After 2022-06-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-28 · Grant · Acquired 20,000 · Balance 20,000 F1: This option shall vest and become exercisable in full upon the earlier to occur of (a) June 28, 2023 or (b) the next annual meeting of the Issuer's stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall vest and become exercisable in full upon the earlier to occur of (a) June 28, 2023 or (b) the next annual meeting of the Issuer's stockholders.
Editas Medicine, Inc.
Report date June 17, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.55 · Expires 2036-06-16 | Direct | 51,700 |
Reported balance
After 2026-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 51,700 · Balance 51,700 F1: This option was granted on June 17, 2026 and is scheduled to vest in full on June 17, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on June 17, 2026 and is scheduled to vest in full on June 17, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 18, 2026 Filed Jun 23, 2026 21:20 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantStock options (right to buy) · Derivative | 14,950 | $0.00 Strike: $34.16 | $0.00 |
DisclosureSEC source: 0001439222-26-000095 · wk-form4_1782249639.xml · derivative · entry 4 Scadden David · CIK 0001707715 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,950 Underlying: Common stock · 14,950 shares Expires 2036-06-18 F4 · derivative.exercise_date: These options were granted on June 18, 2026. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2027. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:20 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock units · Derivative | 2,927 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000095 · wk-form4_1782249639.xml · derivative · entry 3 Scadden David · CIK 0001707715 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,927 Underlying: Common stock · 2,927 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F3 · derivative.expiration_date: The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:20 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 2,816 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000095 · wk-form4_1782249639.xml · derivative · entry 2 Scadden David · CIK 0001707715 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 2,816 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F2 · derivative.expiration_date: The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:20 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 2,816 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000095 · wk-form4_1782249639.xml · nonDerivative · entry 1 Scadden David · CIK 0001707715 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,419 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 20:29 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 51,700 | $0.00 Strike: $2.55 | $0.00 |
DisclosureSEC source: 0001650664-26-000069 · wk-form4_1782160170.xml · derivative · entry 1 Scadden David · CIK 0001707715 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,700 Underlying: Common Stock · 51,700 shares Expires 2036-06-16 F1 · derivative.exercise_date: This option was granted on June 17, 2026 and is scheduled to vest in full on June 17, 2027. Read SEC document |
| November 12, 2025 Filed Nov 14, 2025 21:04 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionStock options (right to buy) · Derivative | 200 | $0.00 Strike: $18.09 | $0.00 |
DisclosureSEC source: 0001439222-25-000120 · wk-form4_1763154293.xml · derivative · entry 3 Scadden David · CIK 0001707715 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,907 Underlying: Common stock · 200 shares Expires 2032-06-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · derivative.exercise_date: This option was granted on June 21, 2022. The shares underlying this option vest 100% one year from grant date. Read SEC document |
| November 12, 2025 Filed Nov 14, 2025 21:04 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 200 | $43.84 | $8,768.00 |
DisclosureSEC source: 0001439222-25-000120 · wk-form4_1763154293.xml · nonDerivative · entry 2 Scadden David · CIK 0001707715 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,603 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| November 12, 2025 Filed Nov 14, 2025 21:04 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 200 | $18.09 | $3,618.00 |
DisclosureSEC source: 0001439222-25-000120 · wk-form4_1763154293.xml · nonDerivative · entry 1 Scadden David · CIK 0001707715 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,803 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| October 08, 2025 Filed Oct 10, 2025 20:18 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionStock options (right to buy) · Derivative | 200 | $0.00 Strike: $18.09 | $0.00 |
DisclosureSEC source: 0001439222-25-000108 · wk-form4_1760127484.xml · derivative · entry 3 Scadden David · CIK 0001707715 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,107 Underlying: Common stock · 200 shares Expires 2032-06-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · derivative.exercise_date: This option was granted on June 21, 2022. The shares underlying this option vest 100% one year from grant date. Read SEC document |
| October 08, 2025 Filed Oct 10, 2025 20:18 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 200 | $41.00 | $8,200.00 |
DisclosureSEC source: 0001439222-25-000108 · wk-form4_1760127484.xml · nonDerivative · entry 2 Scadden David · CIK 0001707715 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,603 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| October 08, 2025 Filed Oct 10, 2025 20:18 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 200 | $18.09 | $3,618.00 |
DisclosureSEC source: 0001439222-25-000108 · wk-form4_1760127484.xml · nonDerivative · entry 1 Scadden David · CIK 0001707715 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,803 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| September 30, 2025 Filed Oct 2, 2025 20:03 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionStock options (right to buy) · Derivative | 200 | $0.00 Strike: $18.09 | $0.00 |
DisclosureSEC source: 0001439222-25-000106 · wk-form4_1759435431.xml · derivative · entry 3 Scadden David · CIK 0001707715 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,307 Underlying: Common stock · 200 shares Expires 2032-06-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · derivative.exercise_date: This option was granted on June 21, 2022. The shares underlying this option vest 100% one year from grant date. Read SEC document |
| September 30, 2025 Filed Oct 2, 2025 20:03 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 200 | $40.00 | $8,000.00 |
DisclosureSEC source: 0001439222-25-000106 · wk-form4_1759435431.xml · nonDerivative · entry 2 Scadden David · CIK 0001707715 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,603 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| September 30, 2025 Filed Oct 2, 2025 20:03 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 200 | $18.09 | $3,618.00 |
DisclosureSEC source: 0001439222-25-000106 · wk-form4_1759435431.xml · nonDerivative · entry 1 Scadden David · CIK 0001707715 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,803 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| August 27, 2025 Filed Aug 29, 2025 20:09 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionStock options (right to buy) · Derivative | 200 | $0.00 Strike: $18.09 | $0.00 |
DisclosureSEC source: 0001439222-25-000100 · wk-form4_1756498139.xml · derivative · entry 3 Scadden David · CIK 0001707715 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,507 Underlying: Common stock · 200 shares Expires 2032-06-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · derivative.exercise_date: This option was granted on June 21, 2022. The shares underlying this option vest 100% one year from grant date. Read SEC document |
| August 27, 2025 Filed Aug 29, 2025 20:09 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 200 | $40.00 | $8,000.00 |
DisclosureSEC source: 0001439222-25-000100 · wk-form4_1756498139.xml · nonDerivative · entry 2 Scadden David · CIK 0001707715 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,603 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| August 27, 2025 Filed Aug 29, 2025 20:09 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 200 | $18.09 | $3,618.00 |
DisclosureSEC source: 0001439222-25-000100 · wk-form4_1756498139.xml · nonDerivative · entry 1 Scadden David · CIK 0001707715 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,803 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| July 10, 2025 Filed Jul 15, 2025 20:05 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionStock options (right to buy) · Derivative | 1,400 | $0.00 Strike: $18.09 | $0.00 |
DisclosureSEC source: 0001439222-25-000084 · wk-form4_1752609950.xml · derivative · entry 3 Scadden David · CIK 0001707715 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,707 Underlying: Common stock · 1,400 shares Expires 2032-06-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · derivative.exercise_date: This option was granted on June 21, 2022. The shares underlying this option vest 100% one year from grant date. Read SEC document |
| July 10, 2025 Filed Jul 15, 2025 20:05 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 1,400 | $40.00 | $56,000.00 |
DisclosureSEC source: 0001439222-25-000084 · wk-form4_1752609950.xml · nonDerivative · entry 2 Scadden David · CIK 0001707715 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,603 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| July 10, 2025 Filed Jul 15, 2025 20:05 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 1,400 | $18.09 | $25,326.00 |
DisclosureSEC source: 0001439222-25-000084 · wk-form4_1752609950.xml · nonDerivative · entry 1 Scadden David · CIK 0001707715 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,003 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| June 20, 2025 Filed Jun 23, 2025 20:18 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 2,120 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-25-000049 · wk-form4_1750709929.xml · derivative · entry 4 Scadden David · CIK 0001707715 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 2,120 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F4 · derivative.exercise_date: The restricted stock units were granted on June 20, 2024. The shares underlying the stock units vest in full on June 20, 2025. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F4 · derivative.expiration_date: The restricted stock units were granted on June 20, 2024. The shares underlying the stock units vest in full on June 20, 2025. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| June 20, 2025 Filed Jun 23, 2025 20:18 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 2,120 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-25-000049 · wk-form4_1750709929.xml · nonDerivative · entry 1 Scadden David · CIK 0001707715 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,603 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 18, 2025 Filed Jun 23, 2025 20:18 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantStock options (right to buy) · Derivative | 15,768 | $0.00 Strike: $35.50 | $0.00 |
DisclosureSEC source: 0001439222-25-000049 · wk-form4_1750709929.xml · derivative · entry 3 Scadden David · CIK 0001707715 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,768 Underlying: Common stock · 15,768 shares Expires 2035-06-18 F3 · derivative.exercise_date: These options were granted on June 18, 2025. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2026. Read SEC document |
| June 18, 2025 Filed Jun 23, 2025 20:18 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock units · Derivative | 2,816 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-25-000049 · wk-form4_1750709929.xml · derivative · entry 2 Scadden David · CIK 0001707715 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,816 Underlying: Common stock · 2,816 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F2 · derivative.expiration_date: The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| June 06, 2025 Filed Jun 10, 2025 20:19 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 37,500 | $0.00 Strike: $1.91 | $0.00 |
DisclosureSEC source: 0001650664-25-000102 · wk-form4_1749586749.xml · derivative · entry 1 Scadden David · CIK 0001707715 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires 2035-06-05 F1 · derivative.exercise_date: This option was granted on June 6, 2025 and is scheduled to vest in full on June 6, 2026. Read SEC document |
| December 11, 2024 Filed Dec 13, 2024 21:04 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionStock options (right to buy) · Derivative | 200 | $0.00 Strike: $18.09 | $0.00 |
DisclosureSEC source: 0001439222-24-000146 · wk-form4_1734123872.xml · derivative · entry 3 Scadden David · CIK 0001707715 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,107 Underlying: Common stock · 200 shares Expires 2032-06-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · derivative.exercise_date: This option was granted on June 21, 2022. The shares underlying this option vest 100% one year from grant date. Read SEC document |
| December 11, 2024 Filed Dec 13, 2024 21:04 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 200 | $46.28 | $9,256.00 |
DisclosureSEC source: 0001439222-24-000146 · wk-form4_1734123872.xml · nonDerivative · entry 2 Scadden David · CIK 0001707715 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,483 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| December 11, 2024 Filed Dec 13, 2024 21:04 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 200 | $18.09 | $3,618.00 |
DisclosureSEC source: 0001439222-24-000146 · wk-form4_1734123872.xml · nonDerivative · entry 1 Scadden David · CIK 0001707715 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,683 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| July 01, 2024 Filed Jul 1, 2024 19:17 UTC | Carisma Therapeutics Inc. CARM · Entity 74418 | GrantStock Option (Right to Buy) · Derivative | 38,700 | $0.00 Strike: $1.67 | $0.00 |
DisclosureSEC source: 0001104659-24-076987 · tm2418517-3_4seq1.xml · derivative · entry 1 Scadden David · CIK 0001707715 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,700 Underlying: Common Stock · 38,700 shares Expires 2034-07-01 F1 · derivative.exercise_date: The shares underlying this option vest over three years in equal monthly installments following July 1, 2024, subject to continued service to Carisma Therapeutics Inc. through the applicable vesting date. Read SEC document |
| June 20, 2024 Filed Jun 24, 2024 20:09 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantStock options (right to buy) · Derivative | 11,774 | $0.00 Strike: $42.45 | $0.00 |
DisclosureSEC source: 0001439222-24-000101 · wk-form4_1719259761.xml · derivative · entry 2 Scadden David · CIK 0001707715 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,774 Underlying: Common stock · 11,774 shares Expires 2034-06-20 F3 · derivative.exercise_date: This option was granted on June 20, 2024. The shares underlying this option vest as to 100% of the underlying shares on June 20, 2025. Read SEC document |
| June 20, 2024 Filed Jun 24, 2024 20:09 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock units · Derivative | 2,120 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-24-000101 · wk-form4_1719259761.xml · derivative · entry 1 Scadden David · CIK 0001707715 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,120 Underlying: Common stock · 2,120 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on June 20, 2024. The shares underlying the stock units will vest in full on June 20, 2025. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F2 · derivative.expiration_date: The restricted stock units were granted on June 20, 2024. The shares underlying the stock units will vest in full on June 20, 2025. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| June 13, 2024 Filed Jun 17, 2024 21:18 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 3,388 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-24-000079 · wk-form4_1718659086.xml · derivative · entry 2 Scadden David · CIK 0001707715 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 3,388 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on June 13, 2023. The shares underlying the stock units vest in full on June 13, 2024. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F2 · derivative.expiration_date: The restricted stock units were granted on June 13, 2023. The shares underlying the stock units vest in full on June 13, 2024. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| June 13, 2024 Filed Jun 17, 2024 21:18 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 3,388 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-24-000079 · wk-form4_1718659086.xml · nonDerivative · entry 1 Scadden David · CIK 0001707715 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,483 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 30, 2024 Filed Jun 3, 2024 21:15 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $5.17 | $0.00 |
DisclosureSEC source: 0001650664-24-000072 · wk-form4_1717449318.xml · derivative · entry 1 Scadden David · CIK 0001707715 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2034-05-29 F1 · derivative.exercise_date: This option was granted on May 30, 2024 and is scheduled to vest in full on May 30, 2025 Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 20:36 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock unit · Derivative | 4,975 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-23-000093 · wk-form4_1687552551.xml · derivative · entry 2 Scadden David · CIK 0001707715 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 4,975 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on June 21, 2022. The shares underlying the stock units will vest in full on June 21, 2023. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F2 · derivative.expiration_date: The restricted stock units were granted on June 21, 2022. The shares underlying the stock units will vest in full on June 21, 2023. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 20:36 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 4,975 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-23-000093 · wk-form4_1687552551.xml · nonDerivative · entry 1 Scadden David · CIK 0001707715 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,095 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 20:28 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantStock options (right to buy) · Derivative | 18,958 | $0.00 Strike: $26.56 | $0.00 |
DisclosureSEC source: 0001439222-23-000083 · wk-form4_1686860874.xml · derivative · entry 2 Scadden David · CIK 0001707715 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,958 Underlying: Common stock · 18,958 shares Expires 2033-06-13 F3 · derivative.exercise_date: This option was granted on June 13, 2023. The shares underlying this option vest as to 100% of the underlying shares on June 13, 2024. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 20:28 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock units · Derivative | 3,388 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-23-000083 · wk-form4_1686860874.xml · derivative · entry 1 Scadden David · CIK 0001707715 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,388 Underlying: Common stock · 3,388 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on June 13, 2023. The shares underlying the stock units will vest in full on June 13, 2024. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F2 · derivative.expiration_date: The restricted stock units were granted on June 13, 2023. The shares underlying the stock units will vest in full on June 13, 2024. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 20:30 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $9.55 | $0.00 |
DisclosureSEC source: 0001415889-23-009233 · form4-06052023_040614.xml · derivative · entry 1 Scadden David · CIK 0001707715 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2033-05-31 F1 · derivative.exercise_date: This option was granted on June 1, 2023 and is scheduled to vest in full on June 1, 2024. Read SEC document |
| June 28, 2022 Filed Jun 30, 2022 22:33 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $1.21 | $0.00 |
DisclosureSEC source: 0000899243-22-024670 · doc4.xml · derivative · entry 1 Scadden David · CIK 0001707715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-06-27 F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (a) June 28, 2023 or (b) the next annual meeting of the Issuer's stockholders. Read SEC document |
| June 21, 2022 Filed Jun 23, 2022 20:11 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantStock options (right to buy) · Derivative | 29,307 | $0.00 Strike: $18.09 | $0.00 |
DisclosureSEC source: 0001439222-22-000065 · wf-form4_165601507916195.xml · derivative · entry 2 Scadden David · CIK 0001707715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,307 Underlying: Common stock · 29,307 shares Expires 2032-06-21 F3 · derivative.exercise_date: This option was granted on June 21, 2022. The shares underlying this option vest as to 100% of the underlying shares on June 21, 2023. Read SEC document |
| June 21, 2022 Filed Jun 23, 2022 20:11 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock unit · Derivative | 4,975 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-22-000065 · wf-form4_165601507916195.xml · derivative · entry 1 Scadden David · CIK 0001707715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,975 Underlying: Common stock · 4,975 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on June 21, 2022. The shares underlying the stock units will vest in full on June 21, 2023. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F2 · derivative.expiration_date: The restricted stock units were granted on June 21, 2022. The shares underlying the stock units will vest in full on June 21, 2023. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| June 09, 2022 Filed Jun 13, 2022 20:30 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $12.31 | $0.00 |
DisclosureSEC source: 0001415889-22-006491 · form4-06132022_040616.xml · derivative · entry 1 Scadden David · CIK 0001707715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-06-08 F1 · derivative.exercise_date: This option was granted on June 9, 2022 and is scheduled to vest in full on June 9, 2023. Read SEC document |
| May 20, 2022 Filed May 24, 2022 20:12 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock unit · Derivative | 1,585 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-22-000053 · wf-form4_165342313322648.xml · derivative · entry 2 Scadden David · CIK 0001707715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 1,585 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on May 20, 2021. The shares underlying the stock units will vest in full on May 20, 2022. Vested shares will be delivered to the reporting person within three business days after such shares become vested F2 · derivative.expiration_date: The restricted stock units were granted on May 20, 2021. The shares underlying the stock units will vest in full on May 20, 2022. Vested shares will be delivered to the reporting person within three business days after such shares become vested Read SEC document |
| May 20, 2022 Filed May 24, 2022 20:12 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 1,585 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-22-000053 · wf-form4_165342313322648.xml · nonDerivative · entry 1 Scadden David · CIK 0001707715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,120 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 03, 2021 Filed Jun 7, 2021 20:14 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 11,538 | $0.00 Strike: $33.36 | $0.00 |
DisclosureSEC source: 0001179110-21-006454 · edgar.xml · derivative · entry 1 Scadden David · CIK 0001707715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,538 Underlying: Common Stock · 11,538 shares Expires 2031-06-02 F1 · derivative.exercise_date: This option was granted on June 3, 2021 and is scheduled to vest in full on June 3, 2022. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 22:30 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 18,188 | $0.00 Strike: $12.91 | $0.00 |
DisclosureSEC source: 0000899243-21-021839 · doc4.xml · derivative · entry 1 Scadden David · CIK 0001707715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,188 Underlying: Common Stock · 18,188 shares Expires 2031-05-31 F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (a) June 1, 2022 or (b) the next annual meeting of the Issuer's stockholders. Read SEC document |
| May 28, 2021 Filed Jun 2, 2021 20:07 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 1,686 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-21-000051 · wf-form4_162266443793602.xml · derivative · entry 2 Scadden David · CIK 0001707715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 1,686 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on May 28, 2020. The shares underlying the stock units will vest in full on May 28, 2021. Vested shares will be delivered to the reporting person within three businessdays after such shares become vested. F2 · derivative.expiration_date: The restricted stock units were granted on May 28, 2020. The shares underlying the stock units will vest in full on May 28, 2021. Vested shares will be delivered to the reporting person within three businessdays after such shares become vested. Read SEC document |
| May 28, 2021 Filed Jun 2, 2021 20:07 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 1,686 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-21-000051 · wf-form4_162266443793602.xml · nonDerivative · entry 1 Scadden David · CIK 0001707715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,535 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 20, 2021 Filed May 24, 2021 20:46 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantStock options (right to buy) · Derivative | 8,888 | $0.00 Strike: $56.76 | $0.00 |
DisclosureSEC source: 0001439222-21-000048 · wf-form4_162188914901072.xml · derivative · entry 2 Scadden David · CIK 0001707715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,888 Underlying: Common stock · 8,888 shares Expires 2031-05-20 F3 · derivative.exercise_date: This option was granted on May 20, 2021. The shares underlying this option vest as to 100% of the underlying shares on May 20, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.